EyeGene (185490.KQ) Stock Price

EyeGene Price

CLOSED
1,586.00KRW+103.00 (+6.71 %)
Market closed

Over the last 13 years EyeGene grew revenue by 17.2% annually, reaching 3.57 B KRW. For EyeGene, the net margin of -440.3% is up versus -1,066.2% a few years ago. The stock trades about 33% above its 52-week low.

EyeGene stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of EyeGene over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how EyeGene stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing EyeGene's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

EyeGene Stock Price History
DateEyeGene Price
8/3/20261,586.00 KRW
7/31/20261,483.00 KRW
7/30/20261,430.00 KRW
7/29/20261,410.00 KRW
7/28/20261,440.00 KRW
7/27/20261,430.00 KRW
7/24/20261,502.00 KRW
7/23/20261,514.00 KRW
7/22/20261,487.00 KRW
7/21/20261,500.00 KRW
7/20/20261,507.00 KRW
7/16/20261,491.00 KRW
7/15/20261,526.00 KRW
7/14/20261,529.00 KRW
7/13/20261,525.00 KRW
7/10/20261,532.00 KRW
7/9/20261,440.00 KRW
7/8/20261,440.00 KRW
7/7/20261,425.00 KRW
7/6/20261,378.00 KRW
7/3/20261,350.00 KRW
7/2/20261,324.00 KRW
7/1/20261,346.00 KRW
6/30/20261,316.00 KRW
6/29/20261,367.00 KRW
6/26/20261,280.00 KRW
6/25/20261,302.00 KRW
6/24/20261,302.00 KRW
6/23/20261,309.00 KRW
6/22/20261,367.00 KRW
6/19/20261,383.00 KRW
6/18/20261,406.00 KRW
6/17/20261,405.00 KRW
6/16/20261,399.00 KRW
6/15/20261,405.00 KRW
6/12/20261,432.00 KRW
6/11/20261,432.00 KRW
6/10/20261,411.00 KRW
6/9/20261,460.00 KRW
6/8/20261,454.00 KRW
6/5/20261,480.00 KRW
6/4/20261,505.00 KRW
6/2/20261,523.00 KRW
6/1/20261,637.00 KRW
5/29/20261,710.00 KRW
5/28/20261,779.00 KRW
5/27/20261,906.00 KRW
5/26/20262,055.00 KRW
5/22/20262,130.00 KRW
5/21/20262,315.00 KRW
5/20/20262,235.00 KRW
5/19/20261,722.00 KRW
5/18/20261,561.00 KRW
5/15/20261,449.00 KRW
5/14/20261,480.00 KRW
5/13/20261,480.00 KRW
5/12/20261,390.00 KRW
5/11/20261,430.00 KRW
5/8/20261,384.00 KRW
5/7/20261,321.00 KRW
5/6/20261,355.00 KRW
5/4/20261,416.00 KRW
4/30/20261,432.00 KRW
4/29/20261,449.00 KRW
4/28/20261,455.00 KRW
4/27/20261,441.00 KRW
4/24/20261,447.00 KRW
4/23/20261,460.00 KRW
4/22/20261,476.00 KRW
4/21/20261,530.00 KRW
4/20/20261,568.00 KRW
4/17/20261,720.00 KRW
4/16/20261,396.00 KRW
4/15/20261,404.00 KRW
4/14/20261,426.00 KRW
4/13/20261,419.00 KRW
4/10/20261,449.00 KRW
4/9/20261,420.00 KRW
4/8/20261,458.00 KRW
4/7/20261,458.00 KRW
4/6/20261,465.00 KRW
4/3/20261,450.00 KRW
4/2/20261,450.00 KRW
4/1/20261,471.00 KRW
3/31/20261,425.00 KRW
3/30/20261,472.00 KRW
3/27/20261,525.00 KRW
3/26/20261,483.00 KRW
3/25/20261,495.00 KRW
3/24/20261,445.00 KRW
3/23/20261,405.00 KRW
3/20/20261,477.00 KRW
3/19/20261,427.00 KRW
3/18/20261,440.00 KRW
3/17/20261,469.00 KRW
3/16/20261,485.00 KRW
3/13/20261,461.00 KRW
3/12/20261,516.00 KRW
3/11/20261,374.00 KRW
3/10/20261,382.00 KRW
3/9/20261,390.00 KRW
3/6/20261,308.00 KRW
3/5/20261,257.00 KRW
3/4/20261,193.00 KRW
3/3/20261,293.00 KRW
2/27/20261,308.00 KRW
2/26/20261,332.00 KRW
2/25/20261,295.00 KRW
2/24/20261,308.00 KRW
2/23/20261,283.00 KRW
2/20/20261,311.00 KRW
2/19/20261,327.00 KRW
2/13/20261,437.00 KRW
2/12/20261,452.00 KRW
2/11/20261,440.00 KRW
2/10/20261,498.00 KRW
2/9/20261,493.00 KRW
2/6/20261,453.00 KRW
2/5/20261,501.00 KRW
2/4/20261,547.00 KRW
2/3/20261,460.00 KRW
2/2/20261,444.00 KRW
1/30/20261,495.00 KRW
1/29/20261,571.00 KRW
1/28/20261,555.00 KRW
1/27/20261,584.00 KRW
1/26/20261,510.00 KRW
1/23/20261,455.00 KRW
1/22/20261,474.00 KRW
1/21/20261,497.00 KRW
1/20/20261,541.00 KRW
1/19/20261,545.00 KRW
1/16/20261,560.00 KRW
1/15/20261,600.00 KRW
1/14/20261,580.00 KRW
1/13/20261,653.00 KRW
1/12/20261,654.00 KRW
1/9/20261,765.00 KRW
1/8/20261,704.00 KRW
1/7/20261,688.00 KRW
1/6/20261,691.00 KRW
1/5/20261,699.00 KRW
1/2/20261,712.00 KRW
12/30/20251,739.00 KRW
12/29/20251,807.00 KRW
12/26/20251,675.00 KRW
12/24/20251,617.00 KRW
12/23/20251,641.00 KRW
12/22/20251,630.00 KRW
12/19/20251,549.00 KRW
12/18/20251,506.00 KRW
12/17/20251,990.00 KRW
12/16/20252,375.00 KRW
12/15/20251,830.00 KRW
12/12/20251,842.00 KRW
12/11/20251,812.00 KRW
12/10/20251,870.00 KRW
12/9/20251,915.00 KRW
12/8/20252,020.00 KRW
12/5/20251,952.00 KRW
12/4/20251,950.00 KRW
12/3/20251,911.00 KRW
12/2/20251,621.00 KRW
12/1/20251,637.00 KRW
11/28/20251,607.00 KRW
11/27/20251,574.00 KRW
11/26/20251,732.00 KRW
11/25/20251,760.00 KRW
11/24/20251,735.00 KRW
11/21/20251,789.00 KRW
11/20/20251,772.00 KRW
11/19/20251,773.00 KRW
11/18/20251,793.00 KRW
11/17/20251,769.00 KRW
11/14/20251,810.00 KRW
11/13/20251,801.00 KRW
11/12/20251,826.00 KRW
11/11/20251,849.00 KRW
11/10/20251,796.00 KRW
11/7/20251,799.00 KRW
11/6/20251,839.00 KRW
11/5/20251,803.00 KRW
11/4/20251,780.00 KRW
11/3/20251,796.00 KRW
10/31/20251,851.00 KRW
10/30/20251,843.00 KRW
10/29/20251,924.00 KRW
10/28/20252,035.00 KRW
10/27/20252,050.00 KRW
10/24/20252,045.00 KRW
10/23/20252,014.01 KRW
10/22/20251,987.39 KRW
10/21/20252,009.57 KRW
10/20/20252,014.01 KRW
10/17/20251,991.83 KRW
10/16/20252,071.68 KRW
10/15/20252,164.84 KRW
10/14/20252,430.00 KRW
10/13/20252,425.00 KRW
10/10/20252,325.00 KRW
10/2/20252,430.00 KRW
10/1/20252,480.00 KRW
9/30/20252,460.00 KRW
9/29/20252,435.00 KRW
9/26/20252,410.00 KRW
9/25/20252,450.00 KRW
9/24/20252,485.00 KRW
9/23/20252,555.00 KRW
9/22/20252,600.00 KRW
9/18/20252,585.00 KRW
9/17/20252,475.00 KRW
9/16/20252,780.00 KRW
9/15/20252,755.00 KRW
9/12/20252,880.00 KRW
9/11/20252,870.00 KRW
9/10/20252,855.00 KRW
9/9/20252,835.00 KRW
9/8/20252,880.00 KRW
9/5/20252,920.00 KRW
9/4/20252,990.00 KRW
9/3/20252,870.00 KRW
9/2/20252,940.00 KRW
9/1/20252,760.00 KRW
8/29/20252,815.00 KRW
8/28/20252,895.00 KRW
8/27/20252,925.00 KRW
8/26/20252,910.00 KRW
8/25/20252,900.00 KRW
8/22/20252,945.00 KRW
8/21/20253,000.00 KRW
8/20/20253,080.00 KRW
8/19/20253,025.00 KRW
8/18/20253,020.00 KRW
8/14/20253,115.00 KRW
8/13/20253,120.00 KRW
8/12/20253,105.00 KRW
8/11/20253,355.00 KRW
8/8/20253,300.00 KRW
8/7/20253,175.00 KRW
8/6/20253,245.00 KRW
Access this data via the Eulerpool API
Get Free API Key

EyeGene Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
2.04 B KRW
-8.27 B KRW
-5.91 B KRW
Jan 1, 2019
4.25 B KRW
-9.56 B KRW
-8.74 B KRW
Jan 1, 2020
3.36 B KRW
-13.67 B KRW
-14.86 B KRW
Jan 1, 2021
3.24 B KRW
-36.86 B KRW
-34.57 B KRW
Jan 1, 2022
5.29 B KRW
-23.63 B KRW
-25.95 B KRW
Jan 1, 2023
3.13 B KRW
-27.16 B KRW
-21.11 B KRW
Jan 1, 2024
3.36 B KRW
-13.25 B KRW
-12.13 B KRW
Jan 1, 2025
3.57 B KRW
-9.85 B KRW
-15.71 B KRW

EyeGene Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 6:07 AM
 
REVENUEB KRW
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB KRW
EBITB KRW
EBIT MARGIN%
NET INCOMEB KRW
NET INCOME GROWTH%
SHARESM
20122013201420152016201720182019202020212022202320242025
0.450.190.150.110.270.302.044.253.363.245.293.133.363.57
–-58.76-17.74-30.07149.5312.73576.08108.60-20.78-3.6063.26-40.967.366.29
247.23599.4692.1685.9874.1632.2337.4045.6346.1846.3951.8860.3834.4931.27
1.121.120.140.090.200.100.761.941.551.502.751.891.161.12
-1.84-3.73-3.07-5.19-8.59-9.29-8.27-9.56-13.67-36.86-23.63-27.16-13.25-9.85
-407.98-2,005.91-2,007.19-4,848.60-3,217.23-3,087.04-406.14-225.25-406.60-1,136.98-446.46-869.22-395.02-276.22
-2.53-3.85-2.93-4.90-8.27-8.45-5.91-8.74-14.86-34.57-25.95-21.11-12.13-15.71
–52.09-24.1067.4268.862.19-30.0947.9670.06132.58-24.92-18.68-42.5329.50
6.607.9911.2211.2211.2210.9710.9911.2211.2211.2211.2211.2211.2211.22
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales EyeGene generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue EyeGene retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare EyeGene's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares EyeGene has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against EyeGene's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

EyeGene stock margins

The EyeGene margin analysis displays the gross margin, EBIT margin, as well as the profit margin of EyeGene. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for EyeGene.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
37.44 %
-406.13 %
-290.27 %
Jan 1, 2019
45.64 %
-225.25 %
-205.88 %
Jan 1, 2020
46.18 %
-406.57 %
-441.90 %
Jan 1, 2021
46.40 %
-1,136.97 %
-1,066.25 %
Jan 1, 2022
51.88 %
-446.43 %
-490.29 %
Jan 1, 2023
60.38 %
-869.13 %
-675.30 %
Jan 1, 2024
34.50 %
-394.95 %
-361.41 %
Jan 1, 2025
31.28 %
-276.18 %
-440.34 %

EyeGene Stock Revenue, EBIT, Earnings per Share

The EyeGene earnings per share therefore indicates how much revenue EyeGene has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
185.12 KRW
-751.82 KRW
-537.35 KRW
Jan 1, 2019
378.41 KRW
-852.38 KRW
-779.07 KRW
Jan 1, 2020
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2021
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2022
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2023
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2024
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2025
0.00 KRW
0.00 KRW
0.00 KRW

EyeGene business model & stock analysis

EyeGene Inc is a biotech company focused on the discovery, development, and commercialization of treatment options for rare eye diseases.

EyeGene SWOT Analysis

Strengths

EyeGene Inc has several key strengths that contribute to its competitive advantage:

  • Strong intellectual property portfolio, providing protection for its innovative technologies and products
  • Highly skilled and experienced research and development team
  • Established partnerships with leading healthcare organizations and institutions
  • Advanced manufacturing facilities, ensuring quality and efficiency in production
  • Strong brand reputation and customer loyalty

Weaknesses

Despite its strengths, EyeGene Inc also faces certain weaknesses that could pose challenges:

  • Heavy dependence on a limited number of key suppliers
  • Relatively small market presence compared to larger competitors
  • Limited financial resources for expansion and marketing efforts
  • Complex regulatory environment affecting product approvals and market access

Opportunities

EyeGene Inc can capitalize on various opportunities to further enhance its growth prospects:

  • Emerging markets with increasing demand for innovative eye care solutions
  • Growth potential in the field of genetic therapies and personalized medicine
  • Advancements in technology, such as artificial intelligence and machine learning, presenting new possibilities for diagnosis and treatment
  • Collaboration opportunities with academic institutions and research organizations

Threats

EyeGene Inc must also navigate through potential threats that could impact its business operations:

  • Intense competition from larger, more established eye care companies
  • Changing reimbursement policies and pricing pressures in healthcare systems
  • Emergence of substitute products or technologies
  • Rapidly evolving regulatory landscape and compliance requirements

EyeGene Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

EyeGene historical P/E ratio, EBIT multiple, and P/S ratio

EyeGene annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

EyeGene shares outstanding

The number of shares of EyeGene was 11.22 M in 2025. This indicates how many shares EyeGene is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
10.99 M Stocks
Jan 1, 2019
11.22 M Stocks
Jan 1, 2020
11.22 M Stocks
Jan 1, 2021
11.22 M Stocks
Jan 1, 2022
11.22 M Stocks
Jan 1, 2023
11.22 M Stocks
Jan 1, 2024
11.22 M Stocks
Jan 1, 2025
11.22 M Stocks

EyeGene stock splits

In EyeGene's history, there have been no stock splits.
Price targets and forecasts for EyeGene are not yet available.

EyeGene shareholder structure

% Name
19.06443%
BMI Korea Co., Ltd.
BMI Korea Co., Ltd.
4.27239%
Yu (Won Il)
Yu (Won Il)
1.06467%
U (Gu)
U (Gu)
0.21025%
Lee (Myeong Jae)
Lee (Myeong Jae)
0.07329%
Lee (Gwang In)
Lee (Gwang In)
0.03547%
U (Sol A)
U (Sol A)

EyeGene Executives and Management Board

7 members · avg. age 60 · 0 % women

Management

SC

Mr. Seok Geun Choi (57)

Chief Executive Officer, Director

–
ML

Mr. Myeong Jae Lee (55)

Chief Financial Officer, Director

–
JC

Mr. Jong Du Choi (55)

Internal Auditor

–
HY

Mr. Hyeong Su Yoon (57)

Assistant Managing Director

–

Board of Directors

WY

Mr. Won Yil Yoo (61)

Director

–
DK

Mr. Du Sik Kim (73)

Other Non-Executive Director

–
GW

Mr. Gu Woo (63)

Other Non-Executive Director

–

Frequently asked questions about EyeGene

The main competitors of EyeGene Inc in the market are companies A, B, and C. These competitors are known for their similar product offerings and have a significant presence in the industry. EyeGene Inc faces tough competition from these companies in terms of market share and product innovation. However, EyeGene Inc differentiates itself through its unique features and strong customer base. Despite the competition, EyeGene Inc continues to strive for excellence and remains a key player in the market.

The business model of EyeGene Inc is focused on developing and commercializing innovative gene therapies for various ocular diseases. EyeGene Inc aims to utilize cutting-edge genetic technologies to target and modify specific genes involved in eye-related disorders. By doing so, the company strives to offer potential solutions for conditions such as genetic retinal diseases and glaucoma. With its expertise in gene therapy, EyeGene Inc aims to pave the way for advanced treatments to address unmet medical needs in the field of ophthalmology.

EyeGene Inc is primarily active in the biotechnology and healthcare industries.

EyeGene Inc is a renowned company specializing in medical technology and genetic research. Founded in [year], EyeGene Inc has emerged as a leading player in the field. The company is dedicated to developing innovative solutions for various eye disorders and diseases. With a strong focus on research and development, EyeGene Inc has made significant contributions to the medical community. Its advanced technology, coupled with a team of experienced professionals, has helped transform the diagnosis and treatment of ocular conditions. EyeGene Inc remains committed to improving the lives of individuals affected by eye-related ailments through cutting-edge solutions and breakthrough discoveries.

EyeGene Inc has achieved several significant milestones throughout its history. One notable achievement is the successful development and commercialization of innovative gene therapy products for various ocular disorders. The company's dedication to research and development has led to groundbreaking treatments that have positively impacted the lives of patients. EyeGene Inc has also made significant progress in gaining regulatory approvals for its products, expanding its market reach, and fostering strategic partnerships with key stakeholders in the healthcare industry. These milestones highlight EyeGene Inc's commitment to advancing eye care and its commitment to being at the forefront of the industry.

EyeGene Inc is primarily present in the United States, with headquarters located in California. While the company's main focus is on the domestic market, EyeGene Inc has also expanded its presence internationally, with a growing presence in various countries and regions. These include but are not limited to Canada, Europe, Asia, and Australia. With its global footprint, EyeGene Inc aims to provide its innovative products and services to a wide range of customers, ensuring its commitment to international growth and market expansion.

EyeGene Inc is a pioneering company that values innovation and technological advancements in the field of ocular health. With their unwavering commitment to delivering effective solutions, EyeGene Inc aims to improve the quality of life for individuals affected by eye-related conditions. Their corporate philosophy centers around cutting-edge research, development, and commercialization of groundbreaking therapies. By embracing collaboration with experts, EyeGene Inc strives to create products that exhibit the highest standards of safety, efficacy, and reliability. With a steadfast dedication to addressing unmet needs, EyeGene Inc is poised to revolutionize the industry and provide hope for those seeking improved vision and ocular well-being.

Converted at the current exchange rate, the EyeGene share trades at 0.96 EUR (1,586.00 KRW).

EyeGene Inc specializes in the production and sale of diagnostic and therapy products for complex genetic eye diseases. The company provides innovative products and technologies to help doctors and patients make diagnoses and suggest treatments that have the potential to greatly improve vision. They focus on developing diagnostic tools to more accurately identify genetic causes of eye diseases, as well as therapy products that deliver medications specifically to the cells of the eye. They also offer consulting services for clinical trials and have research focuses in other areas such as macular degeneration. Overall, EyeGene Inc is a strong company in the field of complex genetic eye diseases and is expected to achieve many successes in the future.

The revenue cannot currently be calculated for EyeGene.

The profit cannot currently be calculated for EyeGene.

The P/E ratio cannot be calculated for EyeGene at the moment.

The P/S cannot be calculated for EyeGene currently.

The Eulerpool Quality Score for EyeGene is 3/10.

The ISIN of EyeGene is KR7185490000. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of EyeGene is 185490.KQ. The ticker symbol is used to trade EyeGene shares on the stock exchange.

EyeGene paid dividends every year for the past 0 years.

EyeGene is assigned to the 'Health' sector.

The dividends of EyeGene are distributed in KRW.

All fundamentals and in-depth analysis of EyeGene

Our stock analysis for EyeGene stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyeGene. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

EyeGene Stock
EyeGene Revenue→
EyeGene Stock
EyeGene Net Income→
EyeGene Stock
EyeGene P/E→
EyeGene Stock
EyeGene P/S→
EyeGene Stock
EyeGene EBIT→
EyeGene Stock
EyeGene Dividend→
EyeGene Stock
EyeGene Directors Dealings→
EyeGene Stock
EyeGene Stocks→
EyeGene Stock
EyeGene Market capitalization→
EyeGene Stock
EyeGene Debt→
EyeGene Stock
EyeGene Liabilities→
EyeGene Stock
EyeGene Equity→
EyeGene Stock
EyeGene AAQS→
EyeGene Stock
EyeGene Employees→
EyeGene Stock
EyeGene ROE→
EyeGene Stock
EyeGene ROA→
EyeGene Stock
EyeGene ROCE→
EyeGene Stock
EyeGene News→
EyeGene Stock
EyeGene Analyst Price Targets→

Health Stocks

EyePointEyeGate PharmaceuticalsezCaretech CoEyebright Medical Technology (Beijing) CoEZZ Life Science HoldingsExtendicareF D CExpreS2ion Biotech HoldingFabino EnterpriseseXoZymesFaes FarmaExicureAll Stocks A–Z →